Biolabex, a Mauritius-based R&D laboratory, has launched its development and manufacturing activities in BioPark Mauritius. Recently accredited as the first GMP-compliant contract development and manufacturing organization (CDMO) in the Indian Ocean, Biolabex provides cosmetics, pharmaceutical, and nutraceutical companies with a full spectrum of R&D and consulting services, from early development, formulation, manufacturing, concept marketing, regulatory affairs, and compliance audits.

“Mauritius is widely regarded as one of the world’s biodiversity hotspots and we saw great potential in locating our first laboratory here,” said Marc Labiche, chief executive officer, Biolabex. “We also have an office in Paris, and this dual presence allows Biolabex, and its clients, to draw benefits from the best of both worlds—close proximity to a rich source of active ingredients and to leading players in the pharmaceutical and cosmetics industries. These factors place Biolabex in a prime position to serve as a global hub.”

Occupying 500 square meters of laboratory space, Biolabex says it is fully equipped with state-of-the-art technology managed by an international team of experts from diverse backgrounds.

With these new activities, Biolabex complements the existing R&D capabilities offered in BioPark Mauritius, the first biotechnological hub in the Indian Ocean. The other key players include CIDP, an internationally recognized contract research organization (CRO), and Quantilab, a multi-disciplinary analytical laboratory specialized in microbiology, organic, and inorganic chemistry. Together, the three partners offer cosmetics, pharmaceutical, and nutraceutical clients a full R&D package, from the sourcing of active ingredients to product commercialization.

The company says it has collaborated with a number of clients, including one of dermatology sector’s largest players.

“For now, our focus is on the cosmetics, pharmaceutical, and nutraceutical market in Europe and the U.S., before looking towards promising markets such as Africa and Asia,” said Mr. Labiche. “Our future plans include expansion of our clientele to other industries, such as medical devices, food supplements, and agriculture.”